prostate cancerprostate-specific antigensalvage radiotherapyFor patients experiencing biochemical recurrence in the absence of distant metastasis, salvage radiotherapy (SRT) with or without androgen deprivation therapy (ADT) is currently the only possible curative treatment option. Prostate-specific antigen (...
More than 40% of men with intermediate-risk or high-risk prostate cancer will experience a biochemical recurrence after radical prostatectomy. Clinical guidelines for the management of these patients largely focus on the use of salvage radiotherapy with or without systemic therapy. However, not all ...
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;112(2):307–14.Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR, Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE). Treatment failure...
In contrast to the primary radiotherapy setting, the benefit of hormone therapy in the sRT setting is less well-defined. Four randomized controlled trials (RCTs) investigated the benefit of adding hormone therapy to sRT (GETUG-AFU 16, RTOG 9601, SPPORT/RTOG 0534, RADICALS-HD). The GETUG-AF...
Boston--The fact that prostate cancer recurrence can be indolent may actually be detrimental to the development of drugs for patients in whom recurrence is life-threatening.
Although 88.9% of patients received androgen deprivation therapy (ADT) postoperatively, the authors say adopting this approach may also help to postpone ADT and prolong biochemical-free survival without ADT. In addition, they found that patients with preoperatively hormone-resistant prostate cancers may...
As focal therapy for prostate cancer becomes more common, it will become the potential need for managing recurrences. Identifying those with suspected recurrence will be the first step accomplished through laboratory evaluation, imaging, and biopsy. While current evidence is limited, options described fo...
Androgen deprivation therapy (ADT) with salvage radiation therapy (RT) improves survival for patients with prostate-specific antigen (PSA) recurrence after radical prostatectomy (RP) for prostate cancer (PC), but many patients suffer further relapse. This study aims to determine the benefit of the ...
Physicians and patients have variable and individual levels of comfort regarding when to begin salvage therapy for rising prostate specific antigen (PSA) after definitive treatment of prostate cancer. The decision to start salvage therapy is a multifacto
Despite local therapy with curative intent, approximately 30% of men suffer from biochemical relapse. Though some of these PSA relapses are not life threatening, many men eventually progress to metastatic disease and die of prostate cancer. Local therapy is an option for some men, but many have...